Christene Huang
Concepts (321)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Swine | 43 | 2024 | 773 | 2.260 |
Why?
| | Diphtheria Toxin | 13 | 2020 | 66 | 1.990 |
Why?
| | Immunotoxins | 12 | 2022 | 55 | 1.850 |
Why?
| | Swine, Miniature | 26 | 2016 | 82 | 1.770 |
Why?
| | Transplantation Chimera | 12 | 2016 | 54 | 1.360 |
Why?
| | Transplantation Conditioning | 9 | 2016 | 170 | 1.210 |
Why?
| | Galectin 3 | 3 | 2022 | 20 | 1.150 |
Why?
| | Hematopoietic Stem Cell Transplantation | 12 | 2016 | 614 | 1.140 |
Why?
| | Lymphocyte Depletion | 9 | 2016 | 135 | 1.140 |
Why?
| | Blood Component Removal | 2 | 2018 | 25 | 1.090 |
Why?
| | Graft Rejection | 12 | 2025 | 620 | 1.020 |
Why?
| | CD3 Complex | 5 | 2013 | 106 | 0.980 |
Why?
| | Graft vs Host Disease | 6 | 2016 | 248 | 0.830 |
Why?
| | Swine Diseases | 5 | 2015 | 8 | 0.790 |
Why?
| | Recombinant Fusion Proteins | 10 | 2020 | 664 | 0.760 |
Why?
| | Transplantation Tolerance | 7 | 2024 | 36 | 0.720 |
Why?
| | Graft Survival | 10 | 2024 | 534 | 0.680 |
Why?
| | Skin Transplantation | 5 | 2016 | 85 | 0.680 |
Why?
| | Lymphoproliferative Disorders | 5 | 2015 | 55 | 0.660 |
Why?
| | Isoantibodies | 5 | 2016 | 60 | 0.630 |
Why?
| | Bone Marrow Transplantation | 7 | 2015 | 287 | 0.620 |
Why?
| | Histocompatibility Antigens | 3 | 2015 | 105 | 0.600 |
Why?
| | Animals | 63 | 2025 | 36847 | 0.590 |
Why?
| | Cell Transplantation | 2 | 2010 | 37 | 0.570 |
Why?
| | Transplantation, Homologous | 8 | 2016 | 415 | 0.560 |
Why?
| | Interleukin-2 | 5 | 2020 | 455 | 0.560 |
Why?
| | T-Lymphocytes, Regulatory | 6 | 2022 | 387 | 0.540 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2019 | 250 | 0.530 |
Why?
| | Immunity, Humoral | 3 | 2015 | 116 | 0.520 |
Why?
| | Lymphocyte Transfusion | 1 | 2016 | 21 | 0.520 |
Why?
| | Transplantation, Haploidentical | 1 | 2016 | 22 | 0.510 |
Why?
| | Blood Donors | 1 | 2016 | 103 | 0.470 |
Why?
| | Receptors, CCR4 | 5 | 2020 | 22 | 0.470 |
Why?
| | Transplantation Immunology | 4 | 2012 | 34 | 0.450 |
Why?
| | T-Lymphocytes | 8 | 2015 | 1993 | 0.450 |
Why?
| | Vascularized Composite Allotransplantation | 2 | 2024 | 31 | 0.440 |
Why?
| | Autoimmunity | 2 | 2022 | 908 | 0.430 |
Why?
| | Cell Lineage | 2 | 2006 | 347 | 0.420 |
Why?
| | Pichia | 8 | 2017 | 20 | 0.420 |
Why?
| | Immunity, Cellular | 3 | 2013 | 268 | 0.410 |
Why?
| | Immunosuppressive Agents | 6 | 2024 | 889 | 0.400 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 5 | 2020 | 81 | 0.400 |
Why?
| | Tissue Engineering | 1 | 2016 | 418 | 0.380 |
Why?
| | Cyclosporine | 7 | 2016 | 268 | 0.380 |
Why?
| | Immune Tolerance | 6 | 2024 | 362 | 0.370 |
Why?
| | Major Histocompatibility Complex | 5 | 2005 | 227 | 0.360 |
Why?
| | Inbreeding | 2 | 2009 | 18 | 0.360 |
Why?
| | Antibodies | 2 | 2012 | 411 | 0.350 |
Why?
| | Transplantation, Heterologous | 4 | 2021 | 194 | 0.340 |
Why?
| | Whole-Body Irradiation | 4 | 2016 | 78 | 0.330 |
Why?
| | Umbilical Cord | 1 | 2010 | 85 | 0.330 |
Why?
| | Inflammation | 4 | 2022 | 2835 | 0.330 |
Why?
| | Hematopoietic Stem Cells | 4 | 2013 | 402 | 0.330 |
Why?
| | Transplantation | 2 | 2012 | 34 | 0.320 |
Why?
| | Flow Cytometry | 11 | 2020 | 1180 | 0.310 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2009 | 121 | 0.300 |
Why?
| | Lymphoma, T-Cell, Cutaneous | 2 | 2020 | 43 | 0.290 |
Why?
| | Liver Diseases | 2 | 2022 | 311 | 0.290 |
Why?
| | CTLA-4 Antigen | 3 | 2013 | 99 | 0.290 |
Why?
| | Thymus Gland | 4 | 2015 | 313 | 0.260 |
Why?
| | Cord Blood Stem Cell Transplantation | 1 | 2007 | 99 | 0.260 |
Why?
| | Chimerism | 1 | 2006 | 31 | 0.260 |
Why?
| | Bone Marrow | 2 | 2010 | 286 | 0.250 |
Why?
| | Histocompatibility Antigens Class I | 4 | 2012 | 202 | 0.250 |
Why?
| | Histocompatibility Antigens Class II | 4 | 2012 | 368 | 0.250 |
Why?
| | Hematologic Neoplasms | 1 | 2007 | 155 | 0.240 |
Why?
| | Galectins | 2 | 2022 | 24 | 0.230 |
Why?
| | Fetal Blood | 1 | 2007 | 327 | 0.230 |
Why?
| | Recombinant Proteins | 7 | 2020 | 1350 | 0.230 |
Why?
| | Corneal Transplantation | 1 | 2025 | 13 | 0.230 |
Why?
| | Myocutaneous Flap | 1 | 2024 | 10 | 0.220 |
Why?
| | Rectus Abdominis | 1 | 2024 | 17 | 0.220 |
Why?
| | Iliac Artery | 1 | 2024 | 55 | 0.220 |
Why?
| | Papio | 3 | 2015 | 93 | 0.220 |
Why?
| | Fiber Optic Technology | 1 | 2023 | 22 | 0.210 |
Why?
| | Tissue Donors | 3 | 2005 | 417 | 0.210 |
Why?
| | Porphyrins | 1 | 2023 | 21 | 0.210 |
Why?
| | Peripheral Blood Stem Cell Transplantation | 1 | 2003 | 24 | 0.210 |
Why?
| | Histocompatibility Testing | 5 | 2015 | 126 | 0.210 |
Why?
| | Cell Line, Tumor | 4 | 2017 | 3405 | 0.210 |
Why?
| | Lymphocyte Culture Test, Mixed | 6 | 2014 | 50 | 0.200 |
Why?
| | Antibodies, Monoclonal | 4 | 2017 | 1430 | 0.200 |
Why?
| | Skin | 3 | 2018 | 751 | 0.200 |
Why?
| | Antibody Specificity | 2 | 2017 | 189 | 0.200 |
Why?
| | Hepatitis, Alcoholic | 1 | 2022 | 13 | 0.190 |
Why?
| | Herpesviridae | 1 | 2022 | 22 | 0.190 |
Why?
| | Muscle Stretching Exercises | 1 | 2022 | 19 | 0.190 |
Why?
| | Yoga | 1 | 2022 | 31 | 0.190 |
Why?
| | Meditation | 1 | 2022 | 31 | 0.190 |
Why?
| | Leukapheresis | 3 | 2013 | 21 | 0.180 |
Why?
| | Histocompatibility | 3 | 2015 | 28 | 0.180 |
Why?
| | Mice, SCID | 5 | 2017 | 366 | 0.180 |
Why?
| | Skin Neoplasms | 2 | 2020 | 852 | 0.170 |
Why?
| | Disease Models, Animal | 8 | 2025 | 4282 | 0.170 |
Why?
| | Immunoglobulin G | 2 | 2017 | 887 | 0.170 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2022 | 99 | 0.170 |
Why?
| | Endogenous Retroviruses | 1 | 2021 | 37 | 0.170 |
Why?
| | Spleen | 3 | 2007 | 514 | 0.170 |
Why?
| | Mice, Inbred NOD | 5 | 2017 | 600 | 0.160 |
Why?
| | Colony-Forming Units Assay | 5 | 2006 | 91 | 0.160 |
Why?
| | Amino Acid Sequence | 6 | 2015 | 2138 | 0.160 |
Why?
| | Lymphoma | 1 | 2021 | 208 | 0.160 |
Why?
| | Hematologic Diseases | 2 | 2012 | 62 | 0.150 |
Why?
| | Base Sequence | 6 | 2015 | 2179 | 0.150 |
Why?
| | Molecular Sequence Data | 6 | 2015 | 2894 | 0.150 |
Why?
| | B7-1 Antigen | 3 | 2013 | 58 | 0.150 |
Why?
| | Time Factors | 7 | 2017 | 6808 | 0.150 |
Why?
| | Interleukin-3 | 2 | 2011 | 25 | 0.150 |
Why?
| | Postoperative Complications | 3 | 2022 | 2639 | 0.150 |
Why?
| | Freund's Adjuvant | 1 | 2018 | 18 | 0.150 |
Why?
| | Kidney Transplantation | 4 | 2005 | 701 | 0.140 |
Why?
| | Antibodies, Heterophile | 2 | 2015 | 14 | 0.140 |
Why?
| | Antigen-Presenting Cells | 2 | 2016 | 156 | 0.140 |
Why?
| | Betacoronavirus | 1 | 2020 | 266 | 0.140 |
Why?
| | Haplotypes | 2 | 2012 | 494 | 0.130 |
Why?
| | Papio hamadryas | 2 | 2013 | 5 | 0.130 |
Why?
| | Antibody Affinity | 1 | 2017 | 60 | 0.130 |
Why?
| | Heterografts | 2 | 2013 | 138 | 0.130 |
Why?
| | Antigens, CD19 | 1 | 2017 | 121 | 0.130 |
Why?
| | Antigens, Heterophile | 1 | 2015 | 5 | 0.120 |
Why?
| | Humans | 27 | 2024 | 136765 | 0.120 |
Why?
| | Immunoconjugates | 1 | 2017 | 114 | 0.120 |
Why?
| | Lymphatic Irradiation | 1 | 2015 | 10 | 0.120 |
Why?
| | Gene Expression | 5 | 2012 | 1500 | 0.120 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 368 | 0.120 |
Why?
| | B-Lymphocytes | 2 | 2015 | 846 | 0.120 |
Why?
| | Polymerase Chain Reaction | 4 | 2012 | 1059 | 0.120 |
Why?
| | Coronavirus Infections | 1 | 2020 | 358 | 0.120 |
Why?
| | Lymphoma, B-Cell | 2 | 2013 | 106 | 0.120 |
Why?
| | Rats | 3 | 2025 | 5639 | 0.110 |
Why?
| | Composite Tissue Allografts | 1 | 2014 | 8 | 0.110 |
Why?
| | Galactosyltransferases | 2 | 2013 | 11 | 0.110 |
Why?
| | Hematopoietic Stem Cell Mobilization | 2 | 2012 | 22 | 0.110 |
Why?
| | Lymphocyte Count | 2 | 2022 | 150 | 0.110 |
Why?
| | Liver Transplantation | 1 | 2022 | 871 | 0.110 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2017 | 851 | 0.110 |
Why?
| | L-Lactate Dehydrogenase | 2 | 2015 | 121 | 0.110 |
Why?
| | Pregnancy, Animal | 1 | 2014 | 52 | 0.110 |
Why?
| | Protein Biosynthesis | 2 | 2013 | 430 | 0.110 |
Why?
| | Retinal Degeneration | 1 | 2014 | 38 | 0.110 |
Why?
| | Antilymphocyte Serum | 1 | 2013 | 64 | 0.110 |
Why?
| | Leukocytes | 1 | 2015 | 311 | 0.110 |
Why?
| | Plasmids | 2 | 2011 | 360 | 0.110 |
Why?
| | Models, Animal | 4 | 2024 | 384 | 0.100 |
Why?
| | Treatment Outcome | 4 | 2024 | 10745 | 0.100 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2014 | 80 | 0.100 |
Why?
| | Mice | 10 | 2022 | 17757 | 0.100 |
Why?
| | Somatosensory Disorders | 1 | 2012 | 1 | 0.100 |
Why?
| | Stem Cell Transplantation | 1 | 2014 | 176 | 0.100 |
Why?
| | DNA Primers | 2 | 2012 | 514 | 0.100 |
Why?
| | Animals, Laboratory | 1 | 2012 | 18 | 0.100 |
Why?
| | Macaca | 1 | 2012 | 56 | 0.100 |
Why?
| | Glycosylation | 4 | 2013 | 151 | 0.100 |
Why?
| | Macaca mulatta | 1 | 2013 | 166 | 0.100 |
Why?
| | Lung Transplantation | 1 | 2015 | 313 | 0.090 |
Why?
| | Escherichia coli Infections | 1 | 2012 | 111 | 0.090 |
Why?
| | Pandemics | 1 | 2020 | 1612 | 0.090 |
Why?
| | Edema | 1 | 2012 | 129 | 0.090 |
Why?
| | Neoplasm Transplantation | 2 | 2013 | 257 | 0.090 |
Why?
| | Immunotherapy | 2 | 2013 | 640 | 0.090 |
Why?
| | Platelet Count | 2 | 2013 | 85 | 0.090 |
Why?
| | CD40 Ligand | 1 | 2010 | 41 | 0.090 |
Why?
| | Prednisolone | 1 | 2010 | 82 | 0.080 |
Why?
| | Injections, Subcutaneous | 1 | 2010 | 154 | 0.080 |
Why?
| | Protein Binding | 5 | 2014 | 2216 | 0.080 |
Why?
| | Monocytes | 2 | 2003 | 563 | 0.080 |
Why?
| | Blood Proteins | 2 | 2022 | 252 | 0.080 |
Why?
| | Leukocytosis | 1 | 2009 | 30 | 0.080 |
Why?
| | Immunization | 1 | 2012 | 411 | 0.080 |
Why?
| | Sus scrofa | 2 | 2012 | 52 | 0.080 |
Why?
| | Lymphocytes | 2 | 2021 | 393 | 0.080 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2020 | 868 | 0.080 |
Why?
| | Antigens, CD | 2 | 2003 | 521 | 0.080 |
Why?
| | Organ Transplantation | 1 | 2013 | 248 | 0.080 |
Why?
| | Immunophenotyping | 2 | 2007 | 319 | 0.080 |
Why?
| | Leukocyte Count | 2 | 2012 | 329 | 0.080 |
Why?
| | Pluripotent Stem Cells | 2 | 2014 | 79 | 0.070 |
Why?
| | Biomarkers | 4 | 2025 | 4144 | 0.070 |
Why?
| | Bone Marrow Cells | 3 | 2006 | 316 | 0.070 |
Why?
| | Antigens | 1 | 2010 | 358 | 0.070 |
Why?
| | Drug Administration Schedule | 1 | 2010 | 785 | 0.070 |
Why?
| | Cytokines | 3 | 2025 | 2084 | 0.070 |
Why?
| | Cell Line | 4 | 2021 | 2838 | 0.070 |
Why?
| | Anemia | 1 | 2009 | 170 | 0.070 |
Why?
| | Autoimmune Diseases | 1 | 2012 | 460 | 0.070 |
Why?
| | Prognosis | 3 | 2022 | 4013 | 0.070 |
Why?
| | Macaca fascicularis | 2 | 2018 | 65 | 0.070 |
Why?
| | Varicellovirus | 1 | 2007 | 17 | 0.070 |
Why?
| | Granulocyte Precursor Cells | 1 | 2006 | 9 | 0.060 |
Why?
| | Neoplasms, Experimental | 1 | 2007 | 176 | 0.060 |
Why?
| | Haploidy | 1 | 2006 | 25 | 0.060 |
Why?
| | Models, Molecular | 1 | 2011 | 1570 | 0.060 |
Why?
| | Glucocorticoids | 1 | 2010 | 593 | 0.060 |
Why?
| | Species Specificity | 3 | 2015 | 586 | 0.060 |
Why?
| | Antineoplastic Agents | 1 | 2017 | 2122 | 0.060 |
Why?
| | Cross Reactions | 2 | 2016 | 133 | 0.060 |
Why?
| | In Vitro Techniques | 2 | 2005 | 1089 | 0.060 |
Why?
| | Cell Separation | 2 | 2002 | 317 | 0.060 |
Why?
| | Allografts | 2 | 2015 | 146 | 0.050 |
Why?
| | Blood Group Incompatibility | 1 | 2004 | 15 | 0.050 |
Why?
| | Erythroid Precursor Cells | 1 | 2003 | 5 | 0.050 |
Why?
| | Female | 8 | 2022 | 72795 | 0.050 |
Why?
| | Pregnancy | 4 | 2015 | 6726 | 0.050 |
Why?
| | Stem Cell Factor | 1 | 2003 | 15 | 0.050 |
Why?
| | Blotting, Southern | 1 | 2003 | 72 | 0.050 |
Why?
| | Uterus | 1 | 2005 | 215 | 0.050 |
Why?
| | Myeloid Progenitor Cells | 1 | 2003 | 17 | 0.050 |
Why?
| | Multipotent Stem Cells | 1 | 2003 | 20 | 0.050 |
Why?
| | Granulocytes | 1 | 2003 | 80 | 0.050 |
Why?
| | Blood Gas Analysis | 1 | 2023 | 74 | 0.050 |
Why?
| | Hindlimb | 1 | 2004 | 128 | 0.050 |
Why?
| | T-Lymphocyte Subsets | 2 | 2022 | 425 | 0.050 |
Why?
| | Fetal Diseases | 1 | 2005 | 173 | 0.050 |
Why?
| | Prenatal Diagnosis | 1 | 2005 | 200 | 0.050 |
Why?
| | Blood Physiological Phenomena | 1 | 2002 | 13 | 0.050 |
Why?
| | Binding, Competitive | 2 | 2014 | 202 | 0.050 |
Why?
| | Oximetry | 1 | 2023 | 96 | 0.050 |
Why?
| | Male | 8 | 2025 | 67311 | 0.050 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2017 | 2052 | 0.050 |
Why?
| | Cell Proliferation | 3 | 2015 | 2475 | 0.050 |
Why?
| | Immunization, Secondary | 1 | 2002 | 89 | 0.050 |
Why?
| | Lung | 1 | 2015 | 4062 | 0.050 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2002 | 173 | 0.050 |
Why?
| | Cells, Cultured | 2 | 2007 | 4191 | 0.050 |
Why?
| | Neoplasms | 1 | 2017 | 2643 | 0.050 |
Why?
| | Patient Acuity | 1 | 2022 | 47 | 0.050 |
Why?
| | Gammaherpesvirinae | 1 | 2002 | 47 | 0.050 |
Why?
| | Neutrophil Infiltration | 1 | 2022 | 107 | 0.050 |
Why?
| | Gene Knockout Techniques | 2 | 2013 | 117 | 0.050 |
Why?
| | Gestational Age | 1 | 2005 | 902 | 0.050 |
Why?
| | Solubility | 2 | 2012 | 245 | 0.050 |
Why?
| | Systemic Inflammatory Response Syndrome | 1 | 2022 | 93 | 0.050 |
Why?
| | Herpesvirus 4, Human | 1 | 2022 | 167 | 0.040 |
Why?
| | Protein Multimerization | 2 | 2014 | 191 | 0.040 |
Why?
| | Genome, Viral | 1 | 2002 | 143 | 0.040 |
Why?
| | Fetus | 1 | 2005 | 806 | 0.040 |
Why?
| | Rabbits | 2 | 2013 | 792 | 0.040 |
Why?
| | Leukocytes, Mononuclear | 2 | 2014 | 558 | 0.040 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2022 | 220 | 0.040 |
Why?
| | Inhibitory Concentration 50 | 1 | 2020 | 90 | 0.040 |
Why?
| | Liver Cirrhosis | 1 | 2022 | 316 | 0.040 |
Why?
| | Protein Processing, Post-Translational | 2 | 2013 | 465 | 0.040 |
Why?
| | Membrane Glycoproteins | 1 | 2002 | 500 | 0.040 |
Why?
| | Viral Proteins | 1 | 2022 | 340 | 0.040 |
Why?
| | Risk | 1 | 2022 | 908 | 0.040 |
Why?
| | DNA | 2 | 2017 | 1458 | 0.040 |
Why?
| | Inflammation Mediators | 1 | 2022 | 513 | 0.040 |
Why?
| | Oxygen | 1 | 2023 | 930 | 0.040 |
Why?
| | Lymphocyte Activation | 1 | 2002 | 1150 | 0.040 |
Why?
| | Mice, Knockout | 2 | 2017 | 3008 | 0.040 |
Why?
| | Safety-Based Drug Withdrawals | 1 | 2017 | 2 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2022 | 2022 | 0.030 |
Why?
| | Tumor Burden | 1 | 2017 | 309 | 0.030 |
Why?
| | Herpesvirus 1, Suid | 1 | 2015 | 2 | 0.030 |
Why?
| | Tumor Virus Infections | 1 | 2015 | 46 | 0.030 |
Why?
| | Calcineurin Inhibitors | 1 | 2015 | 72 | 0.030 |
Why?
| | Tumor Cells, Cultured | 1 | 2017 | 953 | 0.030 |
Why?
| | National Eye Institute (U.S.) | 1 | 2014 | 6 | 0.030 |
Why?
| | Severity of Illness Index | 1 | 2022 | 2822 | 0.030 |
Why?
| | Cell Engineering | 1 | 2014 | 13 | 0.030 |
Why?
| | Regenerative Medicine | 1 | 2014 | 47 | 0.030 |
Why?
| | Cell Survival | 1 | 2017 | 1116 | 0.030 |
Why?
| | Random Allocation | 1 | 2014 | 353 | 0.030 |
Why?
| | Interleukin Receptor Common gamma Subunit | 1 | 2013 | 14 | 0.030 |
Why?
| | Embryonic Stem Cells | 1 | 2014 | 123 | 0.030 |
Why?
| | Blood Cell Count | 1 | 2013 | 55 | 0.030 |
Why?
| | Antigens, CD34 | 1 | 2013 | 88 | 0.020 |
Why?
| | Animals, Genetically Modified | 1 | 2013 | 239 | 0.020 |
Why?
| | Hematocrit | 1 | 2013 | 96 | 0.020 |
Why?
| | Congresses as Topic | 1 | 2014 | 232 | 0.020 |
Why?
| | Protein Interaction Domains and Motifs | 1 | 2013 | 150 | 0.020 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2013 | 374 | 0.020 |
Why?
| | Epitope Mapping | 1 | 2012 | 62 | 0.020 |
Why?
| | Drug Design | 1 | 2013 | 167 | 0.020 |
Why?
| | Lymph Nodes | 2 | 2005 | 492 | 0.020 |
Why?
| | Blotting, Western | 1 | 2014 | 1225 | 0.020 |
Why?
| | Cooperative Behavior | 1 | 2014 | 445 | 0.020 |
Why?
| | Risk Factors | 1 | 2004 | 10325 | 0.020 |
Why?
| | Glycoproteins | 1 | 2012 | 342 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2014 | 1935 | 0.020 |
Why?
| | Prospective Studies | 1 | 2022 | 7572 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 2014 | 1044 | 0.020 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2015 | 605 | 0.020 |
Why?
| | Body Weight | 1 | 2013 | 985 | 0.020 |
Why?
| | Transcription, Genetic | 2 | 2007 | 1455 | 0.020 |
Why?
| | Open Reading Frames | 1 | 2007 | 119 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2006 | 67 | 0.020 |
Why?
| | Conserved Sequence | 1 | 2007 | 239 | 0.020 |
Why?
| | Splenectomy | 1 | 2005 | 62 | 0.020 |
Why?
| | Risk Assessment | 1 | 2014 | 3432 | 0.010 |
Why?
| | Middle Aged | 2 | 2022 | 33228 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2022 | 15504 | 0.010 |
Why?
| | Monitoring, Physiologic | 1 | 2005 | 267 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2014 | 5749 | 0.010 |
Why?
| | Adult | 2 | 2022 | 37631 | 0.010 |
Why?
| | Creatinine | 1 | 2005 | 499 | 0.010 |
Why?
| | Blood Transfusion | 1 | 2005 | 323 | 0.010 |
Why?
| | RNA, Viral | 1 | 2007 | 654 | 0.010 |
Why?
| | Aged | 1 | 2022 | 23794 | 0.010 |
Why?
| | Hybridomas | 1 | 2002 | 237 | 0.010 |
Why?
| | Genes, Viral | 1 | 2002 | 88 | 0.010 |
Why?
| | Anti-Bacterial Agents | 1 | 2012 | 1797 | 0.010 |
Why?
| | Sequence Alignment | 1 | 2002 | 342 | 0.010 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2002 | 385 | 0.010 |
Why?
| | Antigen Presentation | 1 | 2002 | 216 | 0.010 |
Why?
| | Cloning, Molecular | 1 | 2002 | 534 | 0.010 |
Why?
| | Benzimidazoles | 1 | 2002 | 170 | 0.010 |
Why?
| | Bone and Bones | 1 | 2004 | 316 | 0.010 |
Why?
| | Cell Adhesion | 1 | 2002 | 466 | 0.010 |
Why?
| | Cell Division | 1 | 2002 | 796 | 0.010 |
Why?
| | Mammals | 1 | 2002 | 283 | 0.010 |
Why?
| | Fluorescent Dyes | 1 | 2002 | 317 | 0.010 |
Why?
| | Transfection | 1 | 2002 | 941 | 0.010 |
Why?
| | Aorta | 1 | 2002 | 417 | 0.010 |
Why?
| | Sequence Analysis, DNA | 1 | 2002 | 809 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2007 | 2831 | 0.010 |
Why?
| | Phylogeny | 1 | 2002 | 903 | 0.010 |
Why?
| | Kidney | 1 | 2005 | 1467 | 0.010 |
Why?
| | Incidence | 1 | 2004 | 2792 | 0.010 |
Why?
| | United States | 1 | 2014 | 14690 | 0.010 |
Why?
| | Endothelium, Vascular | 1 | 2002 | 926 | 0.010 |
Why?
|
|
Huang's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|